自身抗体在原发性胆汁性胆管炎中的诊断及预后价值

党富涛; 唐映梅

doi:10.3969/j.issn.1001-5256.2020.05.048

自身抗体在原发性胆汁性胆管炎中的诊断及预后价值

DOI: 10.3969/j.issn.1001-5256.2020.05.048

昆明医科大学第二附属医院消化内科

基金项目:

国家自然科学基金项目（81360072,81660102）；

详细信息

中图分类号: R575.7
计量
- 文章访问数: 868
- HTML全文浏览量: 49
- PDF下载量: 172
- 被引次数: 0
出版历程
- 出版日期: 2020-05-20

Diagnostic and prognostic value of autoantibodies in primary biliary cholangitis

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, China

Research funding:

摘要

摘要:
原发性胆汁性胆管炎(PBC)是一种病因不明的自身免疫性胆汁淤积性肝病,肝穿刺活检是重要的诊断手段,但因其有创性,临床运用有限。自身抗体对于PBC有特殊诊断及预后价值,代表性抗体有抗线粒体抗体和抗核抗体,各抗体的临床意义不尽相同。综述了PBC相关自身抗体的诊断及预后意义及相关进展。
- 胆管炎,硬化性 /
- 自身抗体 /
- 诊断 /
- 预后
Abstract:
Primary biliary cholangitis(PBC) is an autoimmune cholestatic liver disease with unknown etiology. Liver biopsy is an important diagnostic tool, but its clinical application is limited due to its invasiveness. Autoantibodies have special diagnostic and prognostic value for PBC, especially anti-mitochondrial antibodies and antinuclear antibodies, and each antibody has unique clinical significance. This article reviews the diagnostic and prognostic significance of autoantibodies associated with PBC and related research advances.
- cholangitis,sclerosing /
- autoantibodies /
- diagnosis /
- prognosis

HTML全文

参考文献(31)

[1] HIRSCHFIELD GM, GERSHWIN ME. The immunobiology and pathophysiology of primary biliary cirrhosis[J]. Annu Rev Pathol, 2013, 8(3):303-330.

[2] JHAVERI MA, KOWDLEY KV. New developments in the treatment of primary biliary cholangitis-role of obeticholic acid[J]. Ther Clin Risk Manag, 2017, 1(3):1053-1060.

[3] WALKER JG, DONIACH D, ROITT IM, et al. Serological tests in diagnosis of primary biliary cirrhosis[J]. Lancet, 1965, 1(7390):827-831.

[4] MACKAY IR, GERSHWIN ME. Molecular basis of mitochondrial autoreactivity in primary biliary cirrhosis[J]. Immunol Today, 1989, 10(31):315-318.

[5] AGMON LN, SHAPIRA Y, SELMI C, et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis[J]. Autoimmun, 2010, 34(8):55-58.

[6] HU SL, ZHAO FR, WANG QS, et al. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis:A meta analysis[J]. Clin Chem Lab Med, 2014, 52(15):1533-1542.

[7] HAN ER, YEO S, KIM MJ, et al. Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis[J]. Clin Chim Acta, 2017, 4(64):113-117.

[8] LU C, HOU XL, LI MW, et al. Detection of AMA-M2 in human saliva:Potentials in diagnosis and monitoring of primary biliary cholangitis[J]. Sci Rep, 2017, 7(1):796-801.

[9] SUN LM, HU HP, LOU JL, et al. An analysis of the serological characteristics of anti-mitochondal M2 subtype in patients with druginduced liver injury and primary biliary cholangitis[J]. Chin J Hepatol, 2019, 27(12):298-303.(in Chinese）孙丽梅，闫惠平，娄金丽，等．抗线粒体抗体M2亚型在药物性肝损与原发性胆汁性胆管炎患者中血清学特点分析[J]．中华肝脏病杂志，2019, 27(12):298-303.

[10] DAHLQVIST G, GAOUAR F, CARRAT F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis[J].Hepatology, 2017, 6(5):152-163.

[11] YAN HP, ZHANG HP, CHEN XX, et al. How to understand the clinical significance of autoantibodies in primary biliary cholangitis[J]. Chin J Hepatol, 2017, 25(11):810-813.(in Chinese）闫惠平，张海萍，陈欣欣．如何认识原发性胆汁性胆管炎自身抗体的临床意义[J]．中华肝脏病杂志，2017, 25(11):810-813.

[12] WESIERSKA GJ, HOHENUER H, HITCHMAN E, et al. Autoantibodies against nucleopor in p62 constitute a novel maker of primary biliary cirrhosis[J]. Gastroenterology, 1996, 1(10):840-847.

[13] BAUER A, HABIOR A. Detection of autoantibodies against nucleoporin p62 in sera of patients with primary biliary cholangitis[J]. Ann Lab Med, 2019, 39(3):291-298.

[14] LI YZ, LIU L, SUN QG, et al. Cloning and expression of nuclear envelope prote in gp210、p62、LBR autoantigene gene as we ll as clinical application of the correlative antibodies in diagnosis of primary biliary cirrhosis[J]. Chin J Lab Med, 2005,28(11):1120-1125.(in Chinese）李永哲，刘镭，孙庆国，等．核包膜蛋白gp210、p62和LBR自身抗原基因克隆表达及其抗体诊断原发性胆汁性肝硬化的价值初探[J]．中华检验医学杂志，2005, 28(11):1120-1125.

[15] NAKAMURA M, KONDO H, MORI T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J]. Hepatology,2007, 45(1):118-127.

[16] SFAKIANAKI O, KOULENTAKI M, TZARDI M, et al. Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients[J]. World J Gastroenterol, 2010, 16(49):4938-4943.

[17] YANG F, YANG Y, WANG Q, et al. The risk predictive values of UK-PBC and GLOBE scoringsystem in Chinese patients with primary biliary cholangitis:The additional effect of antigp210[J]. Aliment Pharmacol Ther, 2017, 45(5):733-743.

[18] HU CJ, DENG CW, SONG G, et al. Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis[J]. Dig Dis Sci, 2011, 56(33):57-63.

[19] HU SL, ZHAO FR, HU Q, et al. Meta-analysis assessment of GP210 and sp100 for the diagnosis of primary biliary cirrhosis[J]. PLoS One, 2014, 9(7):e101916.

[20] LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis:2018 practice guidance from the american association for the study of liver diseases[J]. Hepatology, 2019, 6(9):394-419.

[21] CHAN W, XIAO DZ. Genome-wide association studies of specific antinuclear autoantibody subphenotypes in primary biliary cholangitis[J]. Hepatology, 2019, 7(12):294-307.

[22] GRANITO A, YANG WH, MURATORI L, et al. PML nuclear body component sp140 is a novel autoantigen in primary biliary cirrhosis[J]. Am J Gastroenterol, 2010, 105(1):125-131.

[23] MYTILINAIOU MG, MEYER W, SCHEPER T, et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and sp100 antigens in patients with primary biliary cirrhosis[J]. Clin Chim Acta, 2012, 4(13):1211-1216.

[24] LIU HL, YANG YF. Clinical and pathological features of primary biliary cholangitis with negative anti-mitochondrial antibody[J]. J Clin Hepatol, 2019, 35(3):677-680.(in Chinese）刘红丽，杨永峰．抗线粒体抗体阴性的原发性胆汁性胆管炎的临床及病理特征[J]．临床肝胆病杂志，2019, 35(3):677-680.

[25] JULIUSSON G, IMAM M, BJÖRNSSON ES, et al. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis[J]. Scand J Gastroenterol, 2016, 51(6):745-752.

[26] QIAN JD, WANG GQ. Is autoimmune cholangifis-anti-mitochondrial antibody-negative primary biliary cholangitis still an independent disease?[J]. Chin J Hepatol, 2019, 27(5):393-396.(in Chinese）钱建丹，王贵强．自身免疫性胆管炎—抗线粒体抗体阴性原发性胆汁性胆管炎还是独立的疾病？[J]．中华肝脏病杂志，2019,27(5):393-396.

[27] HESELTINE L, TUNER IB, FUSSEY SP, et al. Primary biliary cinhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation withdisease progression[J].Gastroenterology, 1990, 99(6):1786-1792.

[28] JOSHI S, CAUCH DK, HEATHCOTE EJ, et al. Antimitochondrial antibody profiles:Are they valid prognostic indicators in primary biliary cinrhosis?[J]. Am J Gastroenterol, 2002, 97(4):999-1002.

[29] GRANITO A, YANG WH, MURATORI L, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis[J]. Am J Gastroenterol, 2010, 10(5):25-31.

[30] NORMAN GL, YANG CY, OSTENDORFF HP, et al. Anti-kelchlike 12 and anti-hexokinase 1:Novel autoantibodies in primary biliary cirrhosis[J]. Liver Int, 2015, 35(6):42-51.

[31] NORMAN GL, REIG A, VINAS O, et al. The prevalence of anti-hexokinase-1 and anti-kelch-like 12 peptide antibodies in patients with primary biliary cholangitis is similar in europe and north america:A large international, multi-center study[J]. Front Immunol, 2019, 10(662):1-5.

施引文献

资源附件(0)

访问统计